Fluidx Medical Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Fluidx Medical Technology is a clinical-stage medical device company pioneering next-generation embolic technologies for minimally invasive procedures. Its core innovation is the GPX Embolic Device, a durable liquid embolic designed for deep, distal vessel occlusion, currently under investigation in a pivotal trial with enrollment targeted for completion in January 2026. The company is led by a seasoned team of medtech entrepreneurs and industry veterans, aiming to address significant unmet needs in interventional oncology, particularly for tumor devascularization, and other peripheral embolization procedures. Fluidx operates as a pre-revenue, private entity advancing its product portfolio through clinical development.

Interventional OncologyVascular MalformationsHemorrhage ControlNeurovascular Disorders

Technology Platform

Platform of durable liquid embolic devices designed for controllable, deep distal penetration in peripheral and neurovascular vessels for occlusion.

Opportunities

The growing global embolization market, driven by minimally invasive procedural trends and rising cancer rates, presents a significant opportunity.

Fluidx's deep distal penetration technology addresses a key unmet need in interventional oncology for complete tumor devascularization, potentially capturing share in a high-value segment.

Expansion into the fast-growing neurovascular market, specifically middle meningeal artery embolization, offers a second major growth vector.

Risk Factors

The company faces substantial clinical and regulatory risk, as its lead product is unapproved and must succeed in a pivotal trial.

As a pre-revenue startup, it will also face intense commercialization challenges against large, entrenched competitors with established sales forces and physician relationships.

Technology adoption risk remains if the device does not demonstrate clear superiority or ease-of-use over existing embolics.

Competitive Landscape

Fluidx competes in the embolization market against large, diversified medtech companies like Boston Scientific, Johnson & Johnson (Cerenovus), Medtronic, and Terumo, which offer a range of liquid embolics, coils, and particles. Its key differentiation is the claimed deep distal penetration and controllability of its liquid embolic. It may also compete with newer entrants and specialized companies in the liquid embolic space, such as Varian Medical Systems (now Siemens Healthineers) and other private firms.

More companies in Drug Delivery & Formulation →More companies in United States →